



JEB BUSH, GOVERNOR

RHONDA M. MEDOWS, MD, FAAFP, SECRETARY

October 19, 2001

Dear Pharmacy Provider:

This letter is to inform you of an important change to the Medicaid program. Novolin brand insulins; Novolin 70/30, Novolin N, Novolin R and Novolin L are included in the Medicaid Preferred Drug List (PDL) and are available without prior authorization.

This change affects recipients who use the following insulins: Humulin 70/30, Humulin N, Humulin R and Humulin L. Effective November 15, 2001, these insulins will require prior authorization. After November 15, 2001, claims for Humulin brand prescriptions that have not received prior authorization will be denied. You or the recipient should contact the prescriber. Pharmacists should not call Medicaid for approvals. The prescriber may agree to change the recipient to the Novolin brand or may contact ACS Consultec at (877) 553-7481 to request authorization to continue a non-preferred brand of insulin. Other forms of insulin are not affected by this change.

All recipients and prescribers who routinely receive or prescribe these insulins were mailed a notice of this change. Please communicate this information to any prescriber you feel is not yet aware of this policy.

For additional information, you may contact Medicaid Pharmacy Services at (850) 487-4441.

Sincerely,

A handwritten signature in black ink that reads "George J. Kitchens".

George Kitchens, R.Ph.
Chief, Medicaid Pharmacy Services

A handwritten signature in black ink that reads "J. Darrell Shea".

J. Darrell Shea, M.D.
Chief Medical Officer

